Want to see TSE:AIML full AI Analyst Report?
Top Page
Aiml Resources
(AIML)
Select Model
Select Model
Rating:48Neutral
Price Target:
C$0.07
▲(72.50% Upside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by weak financial performance (declining revenue, large losses, and ongoing cash burn). Technicals provide a meaningful offset with improving price trend and positive momentum. Valuation remains a secondary drag given the negative P/E and lack of dividend data.
Positive Factors
Low Leverage
A debt-to-equity of ~0.11 indicates limited reliance on debt financing, reducing near-term refinancing risk and interest burden. Over 2-6 months this provides balance-sheet flexibility to fund operations or strategic moves without acute leverage pressure, despite operating losses.
Negative Factors
Declining Revenue
A ~25% TTM revenue decline signals weakening top-line scale and potential loss of customers or market traction. Over the next 2-6 months this erodes operating leverage, makes fixed costs harder to cover, and complicates any path to sustainable profitability absent a clear revenue recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
A debt-to-equity of ~0.11 indicates limited reliance on debt financing, reducing near-term refinancing risk and interest burden. Over 2-6 months this provides balance-sheet flexibility to fund operations or strategic moves without acute leverage pressure, despite operating losses.
Read all positive factors
Aiml Resources (AIML) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$10.16M
Dividend YieldN/A
Average Volume (3M)377.83K
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue Growth-37.64%
EPS Growth24.16%
CountryCA
Employees3
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.03
Shares Outstanding253,987,750
10 Day Avg. Volume220,274
30 Day Avg. Volume377,826
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)4.95
Price to Sales (P/S)76.79
P/FCF Ratio-3.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aiml Resources Business Overview & Revenue Model
Company Description
Operating within the digital healthcare sector, AI/ML Innovations Inc. harnesses the power of artificial intelligence (AI) and machine learning (ML). The company's central offering is a patent-pending system for personal health monitoring and mana...
How the Company Makes Money
null...
Aiml Resources Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Jul 2025 | Jul 2024 | Apr 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 125.47K | 167.31K | 600.14K | 487.50K | 65.41K | 0.00 |
| Gross Profit | -487.06K | 162.81K | 294.86K | 466.01K | 65.41K | 0.00 |
| EBITDA | -6.43M | -4.85M | -1.67M | -1.36M | -3.42M | -1.43M |
| Net Income | -7.05M | -4.59M | -3.29M | -1.42M | -3.17M | -2.73M |
Balance Sheet | ||||||
| Total Assets | 1.63M | 3.41M | 329.69K | 1.51M | 2.04M | 3.59M |
| Cash, Cash Equivalents and Short-Term Investments | 442.24K | 2.00M | 216.86K | 14.56K | 525.24K | 3.49M |
| Total Debt | 181.57K | 198.19K | 197.72K | 859.98K | 261.34K | 320.29K |
| Total Liabilities | 1.41M | 855.77K | 1.54M | 1.79M | 1.55M | 1.51M |
| Stockholders Equity | 252.74K | 2.60M | -1.17M | -247.46K | 1.08M | 2.31M |
Cash Flow | ||||||
| Free Cash Flow | -5.25M | -3.99M | -1.64M | -634.28K | -3.02M | -959.00K |
| Operating Cash Flow | -5.24M | -3.99M | -1.64M | -634.28K | -3.02M | -931.35K |
| Investing Cash Flow | -3.72K | -1.15K | -325.98K | -210.64K | -1.14M | -11.38K |
| Financing Cash Flow | 3.83M | 5.78M | 2.16M | 374.37K | 1.27M | 4.17M |
Aiml Resources Technical Analysis
Negative
0.04
Price Trends
0.05
Negative
0.05
Negative
0.05
Negative
Market Momentum
>-0.01
Positive
39.27
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AIML, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.27 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AIML.
Aiml Resources Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$10.16M | -1.18 | -1143.80% | ― | -37.64% | 24.16% | |
45 Neutral | C$32.51M | -6.42 | 9999.00% | ― | -36.92% | 13.03% | |
44 Neutral | C$4.60M | -3.43 | 527.45% | ― | ― | -21.65% | |
42 Neutral | C$6.91M | -2.00 | 6239.15% | ― | ― | 68.00% | |
41 Neutral | C$14.29M | -2.54 | ― | ― | 9.06% | -42.75% | |
40 Underperform | C$4.49M | -1.53 | ― | ― | ― | 86.37% |
* Healthcare Sector Average
TSE:AIML
Aiml Resources
0.04
-0.02
-33.33%
TSE:ADK
Diagnos
0.27
0.08
39.47%
TSE:CHS
Comprehensive Healthcare Systems Inc
0.49
-0.13
-20.48%
TSE:UDOC
UniDoc Health Corp
0.08
-0.13
-61.90%
TSE:NARA
PanGenomic Health, Inc. Class A
0.32
-0.78
-70.91%
TSE:DMED
DiagnaMed Holdings Corp.
0.04
<0.01
16.67%
Aiml Resources Corporate Events
Business Operations and StrategyProduct-Related Announcements
AI/ML Innovations Strikes ECG Tech Reseller Deal in European Digital Cardiology
Positive
Mar 31, 2026
AI/ML Innovations’ subsidiary Neural Cloud Solutions has signed a reseller agreement with a European digital health platform that specializes in cloud-based ECG and heart rate variability analytics. The partner will integrate and resell Neur...
Private Placements and FinancingRegulatory Filings and Compliance
AI/ML Innovations Raises $950,000 in First Tranche of Convertible Debenture Financing
Positive
Mar 27, 2026
AI/ML Innovations Inc. has closed the first tranche of a non-brokered private placement, issuing $950,000 in convertible debentures that can be converted into units at $0.05 per unit, each consisting of a common share and a warrant exercisable at ...
Business Operations and StrategyProduct-Related Announcements
AIML Subsidiary NeuralCloud Taps Baker Institute for AI-Powered ECG Research Deal
Positive
Mar 25, 2026
AI/ML Innovations’ subsidiary NeuralCloud Solutions has signed a research services agreement with Australia’s Baker Heart and Diabetes Institute to provide AI-powered ECG signal processing for a cardiovascular study on heart rate varia...
Private Placements and Financing
AI/ML Innovations Plans $3 Million Convertible Debenture Financing
Positive
Mar 13, 2026
AI/ML Innovations Inc., a global digital health technology company leveraging AI and neural networks to transform biometric data into clinical insights, is listed on the Canadian Securities Exchange, the OTCQB Venture Market and the Frankfurt Stoc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.